Letrozole Eg

Letrozole, the active ingredient in Letrozole Eg, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen production that can fuel tumor growth.

GNH USA supplies Letrozole Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. - Hormone receptor‑positive metastatic breast cancer: reduces tumor progression and improves survival. - Adjuvant therapy for early‑stage HR+ breast cancer: lowers risk of disease recurrence. - Postmenopausal estrogen‑dependent breast cancer: decreases estrogen levels to inhibit tumor growth.

Letrozole may cause a range of adverse reactions, most of which are predictable based on its estrogen‑lowering action.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching discomfort in limbs. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes. - Bone fractures: increased risk due to reduced bone density. - Pulmonary embolism: sudden shortness of breath, chest pain. - Allergic reactions: rash, swelling, anaphylaxis. - Cardiac arrhythmias: QT interval prolongation. - Severe osteoporosis: marked loss of bone mineral density.

Before initiating Letrozole therapy, clinicians should consider several safety measures. - Bone health monitoring: assess bone mineral density regularly. - Liver function tests: evaluate hepatic enzymes before and during treatment. - Cardiovascular assessment: caution in patients with existing heart disease. - Avoid use in premenopausal women: drug is not indicated for this population. - Drug interaction review: check concomitant medications for potential interactions. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole plasma levels. - Estrogen‑containing therapies (e.g., hormone replacement): counteract aromatase inhibition. - Strong CYP2C19 inhibitors (e.g., fluoxetine): may increase letrozole exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may require INR monitoring. - Statins (e.g., simvastatin): potential increase in statin concentrations. - SSRIs (e.g., sertraline): may enhance fatigue or hot flashes. - Anticonvulsants (e.g., phenytoin): monitor for altered efficacy. - Herbal supplements (e.g., St. John’s wort): possible enzyme induction.